Treatment of infectious and inflammatory lesions
AssigneeImmunomedics, Inc.
InventorsHans John Hansen, Milton David Goldenberg
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunomedics, Inc.
InventorsHans John Hansen, Milton David Goldenberg
Estimating the term…
A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific antibodies or antibody fragments, conjugated to at least one imaging agent, wherein at least two of said antibodies or antibody fragments specifically bind to different leukocyte cell types. A method for targeting an imaging agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above anti-leukocyte imaging conjugate. A therapeutic anti-leukocyte antibody-agent conjugate for targeting foci of leukocyte accretion comprises at least one immunoreactive substantially monospecific antibody or antibody fragment which specifically binds to at least one leukocyte cell type, conjugated to at least one therapeutic antimicrobial agent. A method of treatment of an infectious lesion comprises injecting a mammal parenterally with an effective amount for therapy of the above anti-leukocyte therapeutic conjugate.
A polyspecific anti-leukocyte antibody conjugate for enhanced targeting to leukocyte accretion, comprising at least one antimicrobial therapeutic agent conjugated to an immunoreactive polyspecific composite which specifically binds to at least two types of leukocytes, wherein said composite comprises at least two different substantially monospecific antibodies or antibody fragments which are chemically bound to one another either directly or through one or more linkers.
Dependencies are inferred from the claim text.